HomeProductImatinib mesylate
Imatinib mesylate
Imatinib mesylate
220127-57-1
99 %

Imatinib mesylate

Iupac Name:methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
CAS No.: 220127-57-1
Molecular Weight:589.715
Introduction:
Imatinib mesylate, with the chemical formula C30H35N7O4S and CAS registry number 220127-57-1, is a compound known for its therapeutic applications in the treatment of certain types of cancer. This white to off-white crystalline powder is a tyrosine kinase inhibitor, specifically targeting the BCR-ABL fusion protein, which is associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Imatinib mesylate works by inhibiting the abnormal signaling pathways that promote the growth and survival of cancer cells. It is commonly administered orally in the form of tablets or capsules. Imatinib mesylate has been shown to be effective in inducing remission and prolonging survival in patients with CML and ALL. However, it may also cause side effects, including nausea, vomiting, diarrhea, edema, and muscle cramps. Overall, Imatinib mesylate represents a significant advancement in the treatment of certain types of cancer, offering new hope to patients and improving their quality of life.

Chat Now